期刊论文详细信息
Cardiovascular Diabetology
Low fasting glucose is associated with enhanced thrombin generation and unfavorable fibrin clot properties in type 2 diabetic patients with high cardiovascular risk
Anetta Undas2  Jaroslaw Zalewski1  Malgorzata Konieczynska3  Grzegorz Gajos1 
[1] Department of Coronary Disease and Heart Failure, Institute of Cardiology, Jagiellonian University Medical College, 80 Pradnicka str, Krakow, 31-202, Poland;Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland;John Paul II Hospital, Krakow, Poland
关键词: Hypoglycemia;    Fibrin;    Diabetes complications;    Cardiovascular diseases;    Blood glucose;   
Others  :  1209001
DOI  :  10.1186/s12933-015-0207-2
 received in 2015-01-05, accepted in 2015-03-26,  发布年份 2015
PDF
【 摘 要 】

Objective

To investigate the effect of low blood glucose on thrombin generation and fibrin clot properties in type 2 diabetes (T2DM).

Methods

In 165 patients with T2DM and high cardiovascular risk, we measured ex vivo plasma fibrin clot permeation [Ks], turbidity and efficiency of fibrinolysis including clot lysis time [t50%], together with thrombin generation and platelet activation markers in relation to fasting blood glucose.

Results

As compared to patients in medium (4.5-6.0 mmol/l, n = 52) and higher (>6.0 mmol/l, n = 75) glucose group, subjects with low glycemia (<4.5 mmol/l, n = 38) had lower Ks by 11% (p < 0.001) and 8% (p = 0.01), respectively, prolonged t50% by 10% (p < 0.001) and 7% (p = 0.016), respectively, and higher peak thrombin generation by 21% and 16%, respectively (p < 0.001 for both). There were no significant differences in Ks and t50% between patients in medium and higher glucose group. In the whole group, a J-shape relationship was observed between glycemia and the following factors: peak thrombin generation, Ks and t50%. Only in patients with HbA1c < 6.0% (42 mmol/mol) (n = 26) fasting glucose positively correlated with Ks (r = 0.53, P = 0.006) and inversely with t50% (r = −0.46, P = 0.02).

By multiple regression analysis, after adjustment for age, fibrinogen, HbA1c, insulin treatment and T2DM duration, fasting glycemia was the independent predictor of Ks (F = 6.6, df = 2, P = 0.002), t50% (F = 8.0, df = 2, P < 0.001) and peak thrombin generation (F = 13.5, df = 2, P < 0.0001).

Conclusions

In T2DM patients fasting glycemia <4.5 mmol/l is associated with enhanced thrombin formation and formation of denser fibrin clots displaying lower lysability, especially when strict glycemia control was achieved (HbA1c<6.0%).

【 授权许可】

   
2015 Gajos et al.; licensee BioMed Central.

【 预 览 】
附件列表
Files Size Format View
20150601032146128.pdf 900KB PDF download
Figure 5. 39KB Image download
Figure 4. 35KB Image download
Figure 3. 28KB Image download
Figure 2. 31KB Image download
Figure 1. 33KB Image download
【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】
  • [1]Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B et al.. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011; 343:d4169.
  • [2]Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L et al.. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010; 63:1410-1408.
  • [3]Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev. 2008; 24:353-363.
  • [4]Gogitidze Joy N, Hedrington MS, Briscoe VJ, Tate DB, Ertl AC, Davis SN. Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals. Diabetes Care. 2010; 33:1529-1535.
  • [5]Wright RJ, Newby DE, Stirling D, Ludlam CA, Macdonald IA, Frier BM. Effects of acute insulin-induced hypoglycemia on indices of inflammation: putative mechanism for aggravating vascular disease in diabetes. Diabetes Care. 2010; 33:1591-1597.
  • [6]Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care. 2003; 26:688-96.
  • [7]Glycated hemoglobin measurement and prediction of cardiovascular disease. JAM. 2014; 311:1225-33.
  • [8]Rana OA, Byrne CD, Greaves K. Intensive glucose control and hypoglycaemia: a new cardiovascular risk factor? Heart. 2014; 100:21-27.
  • [9]Dunn EJ, Ariëns RA, Grant PJ. The influence of type 2 diabetes on fibrin structure and function. Diabetologia. 2005; 48:1198-1206.
  • [10]Dunn EJ, Philippou H, Ariëns RA, Grant PJ. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia. 2006; 49:1071-1080.
  • [11]Ajjan RA, Gamlen T, Standeven KF, Mughal S, Hess K, Smith KA et al.. Diabetes is associated with posttranslational modifications in plasminogen resulting in reduced plasmin generation and enzyme-specific activity. Blood. 2013; 122:134-142.
  • [12]Jax TW, Peters AJ, Plehn G, Schoebel FC. Hemostatic risk factors in patient with coronary artery disease and type 2 diabetes - a two year follow-up of 24 patients. Cardiovasc Diabetol. 2009; 8:48. BioMed Central Full Text
  • [13]Kuliczkowski W, Greif M, Gąsior M, Kaczmarski J, Pres D, Poloński L. Effect of platelet and inflammatory system activation on outcomes in diabetic patient with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Kardiol Pol. 2011; 69:531-537.
  • [14]Undas A, Ariëns RAS. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolism diseases. Arterioscler, Thromb, Vasc Biol. 2011; 31:e88-99.
  • [15]Konieczyńska M, Fil K, Bazanek M, Undas A. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis. Thromb Haemost. 2014; 111(4):685-93.
  • [16]Undas A. Acquired dysfibrinogenemia in atherosclerotic vascular disease. Pol Arch Med Wewn. 2011; 121:310-318.
  • [17]Ariëns RA. Fibrin(ogen) and thrombotic disease. J Thromb Haemost. 2013; Suppl 1:294-305.
  • [18]Hutton RA, Mikhailidis D, Dormandy KM, Ginsburg J. Platelet aggregation studies during transient hypoglycaemia: a potential method for evaluating platelet function. J Clin Pathol. 1979; 32:434-438.
  • [19]Trovati M, Anfossi G, Cavalot F, Vitali S, Massucco P, Mularoni E et al.. Studies on mechanisms involved in hypoglycemia-induced platelet activation. Diabetes. 1986; 35:818-825.
  • [20]Takeda H, Kishikawa H, Shinohara M, Miyata T, Suzaki K, Fukushima H et al.. Effect of alpha 2-adrenoceptor antagonist on platelet activation during insulin-induced hypoglycaemia in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1988; 31:657-663.
  • [21]Ibbotson SH, Catto A, Davies JA, Grant PJ. The effect of insulin-induced hypoglycaemia on factor VIII:C concentrations and thrombin activity in subjects with type 1 (insulin-dependent) diabetes. Thromb Haemost. 1995; 73:243-246.
  • [22]Fisher BM, Quin JD, Rumley A, Lennie SE, Small M, MacCuish AC et al.. Effects of acute insulin-induced hypoglycaemia on haemostasis, fibrinolysis and haemorheology in insulin-dependent diabetic patients and control subjects. Clin Sci (Lond). 1991; 80:525-531.
  • [23]Chow EYK, Iqbal A, Phoenix F, Heller SR, Ajjan R. Hypoglycaemia promotes thrombosis and inflammation for at least one week in patients with type 2 diabetes (Abstract). Diabetologia. 2013; 56:S243.
  • [24]Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011; 34 Suppl 1:S62-69.
  • [25]Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P et al.. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010; 33:2285-2293.
  • [26]Gajos G, Zalewski J, Rostoff P, Nessler J, Piwowarska W, Undas A. Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot). Arterioscler, Thromb, Vasc Biol. 2011; 31:1696-1702.
  • [27]Undas A, Szuldrzynski K, Stepien E, Zalewski J, Godlewski J, Tracz W et al.. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis. 2008; 196:551-558.
  • [28]Collet JP, Mishal Z, Lesty C, Mirshahi M, Peyne J, Baumelou A et al.. Abnormal fibrin clot architecture in nephritic patients is related to hypofibrinolysis: influence of plasma biochemical modifications. Thromb Haemost. 1999; 82:1482-9.
  • [29]Mills JD, Ariens RA, Mansfield MW, Grant PJ. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation. 2002; 106:1938-1942.
  • [30]Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T. Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in young men. Br J Haematol. 2009; 145:121-12.
  • [31]Al Dieri R, de Laat B, Hemker HC. Thrombin generation: what have we learned? Blood Rev. 2012; 26:197-203.
  • [32]Wolberg AS. Thrombin generation and fibrin clot structure. Blood Rev. 2007; 21:131-142.
  • [33]Buys AV, Van Rooy MJ, Soma P, Van Papendorp D, Lipinski B, Pretorius E. Changes in red blood cell membrane structure in type 2 diabetes: a scanning electron and atomic force microscopy study. Cardiovasc Diabetol. 2013; 12:25. BioMed Central Full Text
  • [34]Pretorius E. The adaptability of red blood cells. Cardiovasc Diabetol. 2013; 12:63. BioMed Central Full Text
  • [35]Lipinski B, Pretorius E. Novel pathway of iron-induced blood coagulation: implications for diabetes mellitus and its complications. Pol Arch Med Wewn. 2012; 122:115-22.
  • [36]Kowalska MA, Rauova L, Poncz M. Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis. Thromb Res. 2010; 125:292-296.
  • [37]Mutch NJ, Engel R, Uitte de Willige S, Philippou H, Ariëns RA. Polyphosphate modifies the fibrin network and down-regulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin. Blood. 2010; 115:3980-3988.
  • [38]Amelot AA, Tagzirt M, Ducouret G, Kuen RL, Le Bonniec BF. Platelet factor 4 (CXCL4) seals blood clots by altering the structure of fibrin. J Biol Chem. 2007; 282:710-20.
  • [39]Undas A, Wiek I, Stepien E, Zmudka K, Tracz W. Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome. Diabetes Care. 2008; 31:1590-5.
  • [40]Jörneskog G, Hansson LO, Wallen NH, Yngen M, Blombäck M. Increased plasma fibrin gel porosity in patients with Type I diabetes during continuous subcutaneous insulin infusion. J Thromb Haemost. 2003; 1:1195-1201.
  • [41]Goto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013; 347:f4533.
  文献评价指标  
  下载次数:103次 浏览次数:25次